GOOCH & HOUSEGO PLC (GHH) — Investment Research Note

Executive summary

Gooch & Housego is a specialist UK-listed photonics engineer designing and manufacturing precision optics, acousto- and electro-optic components, fibre optics and advanced optical sub-systems for aerospace & defence (~35% of FY25 revenue), industrial lasers and semiconductor (~43%), and life sciences (~22%). Over the five-year filing period the business has moved from pandemic disruption and margin compression (FY22-24 adjusted op margins c.6-8%) through portfolio reshaping, four "speed-to-value" acquisitions (GS Optics, Artemis, Phoenix, Global Photonics) and the June-2023 strategic reset toward mid-teens margins — with H1 FY26 showing clear traction (revenue +15.5%, order book £167.3m, A&D up 51.7%). The single most important valuation fact today is the recommended cash takeover at 1,230.0p by Arlington Capital Partners announced 16 July 2026, confirmed by shareholders (scheme Q4 2026); shares are suspended as of 16 October 2026 and the market effectively trades on deal completion odds, not fundamentals.

Fair value estimate

• Fair value range: 1,225p – 1,235p per share, implying £335m – £347m equity value (fully diluted £346m at 28.1m shares).
• Methodology: Transaction value anchor. The 1,230.0p cash scheme consideration (plus 4.9p interim dividend already paid to qualifying holders) represents 25.9x LTM adjusted operating profit and 35.4x LTM adjusted EPS — a c.42% premium to the 15 July 2026 undisturbed price and well above the long-term AIM small-cap photonics multiple. The G&H Board, advised by Investec and Rothschild & Co, has deemed the price "fair and reasonable" relative to precedent sector multiples and internal DCF. No competing bid has emerged in the three-month offer period.
• Independent cross-check: Pre-bid 874p was 19.4x EV/adj op profit and 25.2x P/E — already a full multiple for an AIM photonics specialist running single-digit margins. On a standalone basis a 15-20x fair multiple on current £15.5m LTM adj operating profit would give an EV of £230-310m, i.e. standalone fair value c.700-900p — materially below the bid.
• vs. current £335.3m market cap: 0% to +3% upside to the mid of the range (trade is essentially a merger-arb spread; current 1,225p is a 0.4% gross discount to the 1,230p cash plus the already-detached dividend).

Sector context

Confirmed sector: Technology / Technology Hardware & Equipment (ICB Industry: Technology). G&H's quality/growth profile has historically been below typical photonics peers — single-digit op margins vs. Coherent/Lumentum (10-20%) and specialist UK comparables like Oxford Instruments, Spectris (now itself being taken over), and IQE (compound semi). Closest listed peers: II-VI/Coherent (NASDAQ: COHR), Lumentum (LITE), Oxford Instruments (OXIG.L). G&H is sub-scale against these, with the Board explicitly citing "smaller AIM-listed company" status as a reason to accept the bid.

Investment thesis (at the current 1,225p price — i.e. merger-arb lens)

1. Signed, recommended cash deal at 1,230p with Board unanimity and irrevocable undertakings from directors covering only 0.44% of shares but no shareholder opposition visible 2026-07-16 scheme announcement; 2026-07-30 trading update.
2. Regulatory path manageable — only HSR (US antitrust) and UK NSI Act clearances required; ACP's portfolio makes them a known regulated-sector buyer, with Highwater, Keel and Stellant precedents clearing without issue 2026-07-16 Appendix 1. Long-stop date 16 January 2027.
3. Fundamentals support deal certainty: order book +16.5% CC to £167.3m, A&D revenue +51.7%, FY26 Board expectations maintained even after the 30 July 2026 update warned of Q4 skew 2026-07-30 trading update; 2026-06-02 interims.

Key risks (3 bullets)

1. Scheme fails or is reduced — Bidco reserves right to reduce consideration for additional dividends; germanium cost inflation and FY26 Q4-weighting mean a profit miss could theoretically give Bidco grounds to walk, though no MAC is specifically invoked 2026-07-16 Appendix 1 Conditions 3.6-3.8.
2. Regulatory delay past 16 January 2027 Long Stop Date — NSI Act review in UK optics/defence context is non-trivial given G&H's role as "trusted supplier to defence programmes critical to the UK, US and their allies" 2026-07-16 scheme announcement.
3. Standalone downside case — if the deal breaks, shares likely retrace toward the pre-bid 874p area or lower (c.-29%), especially given Life Sciences margin collapse to 4.6% in H1 FY26, germanium raw-material pressure and the acknowledged capacity/supply-chain constraints 2026-06-02 interims; 2026-07-30 trading update.

Operating leverage

G&H is a classic specialty-industrial with meaningful but not spectacular operating leverage. The fixed-cost footprint is 11 manufacturing sites (post Baltimore/St Asaph/Shanghai consolidation) plus R&D centres in Ashford, Rochester NY and the US Tampa life-sciences hub; R&D ran at £3.9m in H1 FY26 (4.8% of sales) and is largely fixed. Gross margin was 29.4% in H1 FY26 (FY25: 31.0%). The published mid-teens margin target against the current 8.8% H1 FY26 adjusted op margin implies the business believes incremental revenue carries c.25-30% contribution margin — plausible given utilisation ramp at Moorpark and Ilminster precision-optics sites which have been bottleneck-constrained 2026-06-02 interims. On a +10-20% revenue surprise, I estimate operating profit would rise +40-70% (so c.£22-27m vs. current £15.5m LTM) — meaningful but not transformational. This is a 50-60 operating-leverage profile, not a software-like 80+. The germanium cost shock and raw-material volatility in FY26 are evidence the leverage cuts both ways.

Value-trap signals

None identified at the current price given the signed cash bid. On a standalone/pre-bid basis one could note: (i) repeated H2-weighting warnings and FY24 profit miss (August 2024 trading update cut PBT by £1.5m), (ii) Life Sciences margin collapse from 12.0% to 4.6% H1-over-H1, (iii) germanium exposure to Chinese export controls, (iv) sub-scale AIM listing with liquidity drag — the Board itself cited these as reasons to accept the ACP offer.

Earnings vs. expectations

• FY23 (Oct 2023 TU): Trading "slightly ahead of expectations" — modest beat.
• FY24 H1 (Jun 2024 interims): In line; EM4 divested, non-underlying hit (£9.3m).
• FY24 (Aug 2024 TU): Miss — adjusted PBT c.£1.5m below prior expectations due to supplier/customer delays; delivered £8.1m adj PBT.
• FY25 H1 (Jun 2025 interims): Adjusted PBT up 91% YoY to £5.1m — strong, in line with upgraded expectations.
• FY25 (Oct 2025 TU): "Broadly in line" on revenue and adj PBT; some ancillary costs higher.
• FY26 H1 (Jun 2026 interims): Adj PBT +13.9% to £5.8m, in line.
• FY26 (Jul 2026 TU): Expectations maintained but H2 skew more pronounced — effectively a soft warning.

Pattern: more hits than clean beats, with FY24 the clear miss. A "mixed but improving" track record — scores c.40-50 on the surprise trend scale.

Conviction

5 — very high. The fair-value call is anchored to a signed, recommended, financed cash offer with high regulatory probability and a long-stop only 90 days out. The only meaningful uncertainty is deal timing/break risk, which the current ~0.4% discount to the cash price fairly captures. Supporting: (i) unanimous Board recommendation with Rule 3 advice from Investec and Rothschild, (ii) ACP's deep A&D/defence M&A track record (BlueHalo, Stellant, Exostar), (iii) 42% premium to undisturbed and 46% to 6-month VWAP leaves little room for a bump. Limiting: (i) NSI Act clearance is non-trivial for a UK defence-content optics business, (ii) if the scheme breaks, standalone fair value is materially below current.

Driver scoring

• ai_beneficiary (50): Legitimate semiconductor-capital-equipment exposure (DUV/EUV lithography components, germanium acousto-optic modulators for CO2 lasers), subsea data-cable fibre-optic couplers that carry AI training traffic, and growing optical interconnect / space laser-comms work — real but not pure-play AI exposure.
• operating_leverage (55): Mid-teens margin target vs. c.9% current, high-fixed-cost R&D and 11-site footprint, but asset-heavy specialty industrial, not software; incremental revenue carries meaningful but not disproportionate drop-through.
• earnings_surprise_trend (45): FY24 miss, several H2-weighting qualifications in FY25 and FY26; mostly meets but has missed when supply chain or customer timing turned.
• cyclicality (55): Semi-cyclical industrial, A&D counter-cyclical; blended moderate exposure.
• moat (55): Technical expertise in super-polished optics for ring-laser gyros, germanium coatings, long defence qualification cycles — narrow moat, execution-based.
• leverage (35): Net debt 1.5x EBITDA at 31 March 2026 (£49.8m incl. IFRS16); manageable but has drifted up with M&A.
• earnings_quality (60): Persistent non-underlying items (acquisition costs, restructuring, site closure, litigation) make underlying picture a bit noisy; cash conversion decent.
• management_quality (55): Peppiatt-led strategy refresh since Sept 2022 is tracking, four acquisitions executed, portfolio reshaped (EM4 divested, Pockels cells exited); some execution misses but credible.
• growth_momentum (65): H1 FY26 revenue +15.5%, order book +16.5% CC to £167.3m record, A&D +51.7%; momentum is strong going into the take-private.

Overall score: 180 / 1000

Rationale: This is a locked-in merger arbitrage situation with ~0.6% expected return to deal close. For an investor seeking AI-receiver exposure with operating leverage to long-tail upside, GHH is structurally the wrong instrument today — the upside is capped at 1,235p regardless of what happens in semis, defence or AI capex. The AI/photonics thesis has been monetised by Arlington Capital Partners at 25.9x operating profit; public shareholders get cash. Low fit for the stated strategy.